PRESS RELEASE PR Newswire
Apr. 13, 2022, 06:00 AM
Nuvaxovid™ is the first protein-based COVID-19 vaccine authorized for use in Switzerland
GAITHERSBURG, Md., April 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and...
SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS
GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation...
50 microgram matrix m adjuvant
chiefexecutiveofficernovavaxchiefexecutiveofficer sk bioscience
coronavirus spike s protein
country: unknown
novavax' recombinant nanoparticle technology
protein based vaccine candidate
saponin based matrix m adjuvant
stanley c erck president
two pivotal phase 3 trials